- Home
- ACHR vs ELVN Comparison
ACHR vs ELVN Comparison
Compare ACHR & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACHR | ELVN |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.2B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACHR | ELVN |
|---|---|---|
| Price | $5.51 | $57.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $12.00 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 31.1M | 782.5K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.28 | 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $300,000.00 | N/A |
| Revenue This Year | $4,986.67 | N/A |
| Revenue Next Year | $876.87 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.30 | $14.79 |
| 52 Week High | $14.62 | $62.32 |
Technical Indicators
Market Signals| Indicator | ACHR | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 46.19 | 47.59 |
| Support Level | $5.51 | $56.51 |
| Resistance Level | $5.59 | $62.16 |
| Average True Range (ATR) | 0.25 | 2.00 |
| MACD | -0.08 | -0.47 |
| Stochastic Oscillator | 10.05 | 22.22 |
Price Performance
Historical ComparisonAbout ACHR Archer Aviation Inc.
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner. The company is building a platform to deliver aircraft, technologies, and services to customers world-wide across commercial and defense sectors.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.